Orchestra Biomed Holdings In (OBIO) — 13F Filings Explorer (Q2 2026)

OBIO ranks #5142 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

78 institutions disclose a position in OBIO, but none treat it as a major bet — even Propel Bio Management, LLC, its most concentrated holder, allocates just 2.0% of its own portfolio to it.

BlackRock has added to its OBIO position for two straight quarters, increasing it by $8.2M to reach $10.8M today.

Affinity Asset Advisors, LLC has trimmed its OBIO position for two straight quarters, cutting it by $2.2M while still holding $144.1K.

OBIO is down 1.9% today, but institutions show net buying of $28.0M this quarter — a divergence between today's price move and the underlying institutional flow.

OBIO reported a net loss of $59.0M over the trailing twelve months.

• Not yet profitable — net loss of $59.0M over the trailing twelve months
• Revenue grew 986.1% year over year
• Net income improved year over year, from -$69.7M to -$59.0M
• Operating cash flow was negative, using $49.0M in cash
• Current ratio of 6.45x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.96x equity — within a conventional range